Vistin Pharma ASA
Vistin Pharma ASA, through its subsidiary, Vistin Pharma AS, engages in the production and sale of active pharmaceutical ingredients (APIs) worldwide. It offers metformin HCl APIs and direct compressive granulates for the pharmaceutical industry. The company was founded in 1969 and is based in Oslo, Norway.
Vistin Pharma ASA (VISTN) - Net Assets
Latest net assets as of June 2025: Nkr294.27 Million NOK
Based on the latest financial reports, Vistin Pharma ASA (VISTN) has net assets worth Nkr294.27 Million NOK as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Nkr421.72 Million) and total liabilities (Nkr127.45 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Nkr294.27 Million |
| % of Total Assets | 69.78% |
| Annual Growth Rate | 6.53% |
| 5-Year Change | 13.63% |
| 10-Year Change | N/A |
| Growth Volatility | 67.46 |
Vistin Pharma ASA - Net Assets Trend (2016–2024)
This chart illustrates how Vistin Pharma ASA's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Vistin Pharma ASA (2016–2024)
The table below shows the annual net assets of Vistin Pharma ASA from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | Nkr309.53 Million | -4.10% |
| 2023-12-31 | Nkr322.77 Million | +18.12% |
| 2022-12-31 | Nkr273.26 Million | -0.95% |
| 2021-12-31 | Nkr275.89 Million | +1.28% |
| 2020-12-31 | Nkr272.40 Million | -34.11% |
| 2019-12-31 | Nkr413.40 Million | +18.50% |
| 2018-12-31 | Nkr348.85 Million | +190.33% |
| 2017-12-31 | Nkr120.16 Million | -35.61% |
| 2016-12-31 | Nkr186.61 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Vistin Pharma ASA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 324.1% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Nkr135.89 Million | 43.90% |
| Other Components | Nkr173.64 Million | 56.10% |
| Total Equity | Nkr309.53 Million | 100.00% |
Vistin Pharma ASA Competitors by Market Cap
The table below lists competitors of Vistin Pharma ASA ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ICC Holdings Inc
NASDAQ:ICCH
|
$40.47 Million |
|
Gentian Diagnostics AS
OL:GENT
|
$40.48 Million |
|
Ambika Cotton Mills Limited
NSE:AMBIKCO
|
$40.48 Million |
|
Hong Leong Capital Bhd
KLSE:5274
|
$40.48 Million |
|
Aprogen KIC Inc
KO:007460
|
$40.47 Million |
|
SDN Company. Ltd
KQ:099220
|
$40.47 Million |
|
CAPITAL + REGIONAL LS-01
F:XC2R
|
$40.47 Million |
|
Eusu Holdings
KO:000700
|
$40.44 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Vistin Pharma ASA's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 322,770,000 to 309,529,000, a change of -13,241,000 (-4.1%).
- Net income of 62,750,000 contributed positively to equity growth.
- Dividend payments of 77,587,000 reduced retained earnings.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Nkr62.75 Million | +20.27% |
| Dividends Paid | Nkr77.59 Million | -25.07% |
| Other Changes | Nkr1.60 Million | +0.52% |
| Total Change | Nkr- | -4.10% |
Book Value vs Market Value Analysis
This analysis compares Vistin Pharma ASA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.15x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 2.01x to 3.15x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | Nkr10.94 | Nkr22.00 | x |
| 2017-12-31 | Nkr6.89 | Nkr22.00 | x |
| 2018-12-31 | Nkr7.87 | Nkr22.00 | x |
| 2019-12-31 | Nkr9.32 | Nkr22.00 | x |
| 2020-12-31 | Nkr6.14 | Nkr22.00 | x |
| 2021-12-31 | Nkr6.22 | Nkr22.00 | x |
| 2022-12-31 | Nkr6.16 | Nkr22.00 | x |
| 2023-12-31 | Nkr7.28 | Nkr22.00 | x |
| 2024-12-31 | Nkr6.98 | Nkr22.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Vistin Pharma ASA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 20.27%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 14.62%
- • Asset Turnover: 1.11x
- • Equity Multiplier: 1.24x
- Recent ROE (20.27%) is above the historical average (7.39%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 6.92% | 7.58% | 0.61x | 1.50x | Nkr-5.74 Million |
| 2017 | 58.59% | 39.84% | 0.76x | 1.93x | Nkr58.38 Million |
| 2018 | -21.11% | -37.00% | 0.40x | 1.43x | Nkr-108.51 Million |
| 2019 | 16.01% | 29.14% | 0.45x | 1.22x | Nkr24.86 Million |
| 2020 | -35.59% | -38.30% | 0.79x | 1.18x | Nkr-124.20 Million |
| 2021 | 9.05% | 8.96% | 0.84x | 1.21x | Nkr-2.63 Million |
| 2022 | -1.73% | -1.64% | 0.71x | 1.49x | Nkr-32.04 Million |
| 2023 | 14.13% | 10.47% | 1.08x | 1.25x | Nkr13.32 Million |
| 2024 | 20.27% | 14.62% | 1.11x | 1.24x | Nkr31.80 Million |
Industry Comparison
This section compares Vistin Pharma ASA's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $501,716,000
- Average return on equity (ROE) among peers: -0.67%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Vistin Pharma ASA (VISTN) | Nkr294.27 Million | 6.92% | 0.43x | $40.47 Million |
| Photocure (PHO) | $501.72 Million | -0.67% | 0.47x | $114.80 Million |